TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02241421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03014180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Clinic LVAT
Description: Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
Study: NCT04514536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health monitors
Description: * The connected scale (iHealth HS2) measures weight from 5 to 180kg and BMI.~* The connected actimeter (iHealth AM4) monitors activity (number of steps, distance, calories), sleep (automatic sleep recognition, effective sleep time, number of awakenings) and swimming (automatic activity recognition, session duration, swim type recognition and number of laps).~* The connected blood pressure monitor (iHealth Track KN-550BT)is a medical device that measures blood pressure and pulse rate.~* The activity monitor (manufactured by RF Track) consists of a housing that can be positioned as a pendant or at the hip. It includes an accelerometer, gyroscope, magnetometer, barometer, radio transceiver, and led. The sensor records the raw signals.~* The touchpad allows the subject to connect to the Calliope app. This app allows the data recovery, storage, analysis, visualization, and all the required settings for the platform to work together.
Study: NCT02409147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Transplant
Description: Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
Study: NCT04189796

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Cheese
Description: Daily oral intake of cheese

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cheese
Description: Daily oral intake of cheese
Study: NCT04651764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColubrisMX Endoluminal Surgical (ELS) System
Description: Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
Study: NCT03519841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.1
Description: Investigational Medical Device collecting spectral Raman data from tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.1
Description: Investigational Medical Device collecting spectral Raman data from tissue.
Study: NCT04356209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PRO Intervention
Description: Statements of symptoms and patients' health status (PROs) will be collected via a web interface, including access and use in patients with burden symptoms.~The platform will include four items concerning 7 side effects of fibrosis of grade \> 2 in breast cancer. Patients will be encouraged to evaluate on a 5-point Likert scale the frequency, the intensity and the repercussions on the daily life of some symptoms during the last 7 days, in particular on:~* general pain~* anxiety~* sadness~* texture of the treated breast~* Patients will also be invited to express themselves on the severity of two other symptoms of their choice, to their worst degree, by listing and rating them on a 5-point scale ranging from None to Very severe Finally, the aesthetic impact will be evaluated by patients on a visual analogue scale (VAS) of 0 to 100mm
Study: NCT03740399

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Investigators will perform spinal anesthesia for section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Investigators will perform spinal anesthesia for section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Investigators will perform spinal anesthesia for section
Study: NCT03000556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% Sodium Hyaluronate Eye Drop
Description: The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
Study: NCT03313635

Intervention type: DIAGNOSTIC_TEST
Intervention: Men presenting with low-T
Description: Evaluation of prealbumin levels.
Study: NCT04248712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 40 mg tab twice daily by mouth for 12 week duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 10 mg tab once daily by mouth for 12 week duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains no active ingredient
Study: NCT04013269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb-Therapy
Description: Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
Study: NCT01966354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Internal jugular venous approach
Description: The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Internal jugular venous approach
Description: The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Internal jugular venous approach
Description: The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane).
Study: NCT01322724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm vs Cool water
Description: Body vs Room temperature water used during insertion of colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Warm vs Cool water
Description: Body vs Room temperature water used during insertion of colonoscopy
Study: NCT00936637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed infant formula
Study: NCT04098887

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice stereotactic body radiation therapy
Description: For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
Study: NCT03138317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma
Description: This group will receive a knee injection with 6 ml of plasma.
Study: NCT01948466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercials
Description: These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
Study: NCT03138317

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive a knee injection with 6 ml saline solution.
Study: NCT03910725

Intervention type: OTHER
Intervention: Electrocardiographic imaging
Description: ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.

Intervention type: OTHER
Intervention: Electrocardiographic imaging
Description: ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.

Intervention type: OTHER
Intervention: Electrocardiographic imaging
Description: ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
Study: NCT04356209

Intervention type: DRUG
Group type: OTHER
Intervention: Pravastatin
Description: All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
Study: NCT00671398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally for one night only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 16 mg, tablets, orally for one night only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally for one night only
Study: NCT00436020

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Sham Transcranial Magnetic Stimulation
Study: NCT02057367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scalp block with 0.5% plain Marcaine
Description: Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
Study: NCT01282255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC109-0012
Description: The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
Study: NCT03380637

Intervention type: OTHER
Intervention: ultrasound
Description: Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
Study: NCT02391311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
Study: NCT00879723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin and Mineral supplementation
Description: IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg.
Study: NCT02057367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scalp block with 0.9% normal saline
Description: Anterior scalp block will be done by using 0.9% normal saline 20 ml.
Study: NCT04569084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Oral edaravone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Oral edaravone
Study: NCT01957293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: single oral administration, 4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral administration
Study: NCT01618058

Intervention type: DRUG
Intervention: No Investigational Product
Description: This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants

Intervention type: DRUG
Intervention: No Investigational Product
Description: This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants
Study: NCT03340285

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AkP06
Description: first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
Study: NCT04555863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: haMSter smartphone app
Description: the app tracks patient reported outcomes
Study: NCT04569084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT01729104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I.
Study: NCT03752996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE TF™ Aortic Valve System
Description: Transcatheter Aortic Valve Implantation
Study: NCT04348812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT
Description: mobile attention bias modification training for anxiety, using the app Personal Zen

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: ABMT
Description: mobile attention bias modification training for anxiety, using the app Personal Zen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
Study: NCT01322854

Intervention type: RADIATION
Group type: OTHER
Intervention: IMRT with an simultaneous integrated boost
Description: IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT with an simultaneous integrated boost
Description: IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
Study: NCT00620373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging
Description: Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Mammography
Description: Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium (99mTc) sestamibi
Description: Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
Study: NCT02871349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: An MRI will be performed on participants aged 15-24 years.
Study: NCT01729104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
Study: NCT00821860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: talc
Description: Talc pleurodesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic thoracoscopy
Description: Talc pleurodesis via thoracoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic videothoracoscopy
Description: Video-assisted thoracoscopic pleurectomy
Study: NCT02621255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia type of performed for patient which has femur fracture.
Study: NCT01747070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS and EAC sham
Description: The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: tDCS sham and EAC sham
Description: For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
Study: NCT02621255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Anesthesia type of performed for patient which has femur fracture.
Study: NCT00042458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide acetate
Description: Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
Study: NCT02519335

Intervention type: DRUG
Group type: OTHER
Intervention: Dexrazoxane
Description: Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
Study: NCT03543241

Intervention type: DIAGNOSTIC_TEST
Intervention: MyoStrain
Description: Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.
Study: NCT00758680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
Study: NCT02871349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: An MRI will be performed on participants aged 15-24 years.
Study: NCT00688467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: 30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: 30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2